'tAnGo', A Phase III Randomised Trial Of Gemcitabine In Paclitaxel-Containing, Epirubicin-Based, Adjuvant Chemotherapy For ER/PgR-Poor, Early Stage, Breast Cancer
Phase of Trial: Phase III
Latest Information Update: 19 May 2017
At a glance
- Drugs Gemcitabine (Primary) ; Cyclophosphamide; Epirubicin; Paclitaxel
- Indications Breast cancer; Early breast cancer
- Focus Adverse reactions; Registrational; Therapeutic Use
- Acronyms tAnGo
- 10 May 2017 Status changed from active, no longer recruiting to completed.
- 28 Feb 2012 Company added as trial sponsor and additional lead trial investigator identified as reported by UKCRN.
- 07 Apr 2009 Additional lead trial investigator Christopher Poole identified as reported by United Kingdom Clinical Research Network record.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History